Africa Finance Today
SEE OTHER BRANDS

The best finance and banking news from Africa

Africa Finance Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa Finance Today.

Press releases published on May 8, 2025

American Coastal Insurance Corporation Reports Financial Results for its First Quarter Ended March 31, 2025

American Coastal Insurance Corporation Reports Financial Results for its First Quarter Ended March 31, 2025

Company to Host Quarterly Conference Call at 5:00 P.M. ET on May 8, 2025 The information in this press release should be read in conjunction with an earnings presentation that is available on the Company's website at investors.amcoastal.com/Presentations. …

LPL Financial Announces First Quarter 2025 Results

LPL Financial Announces First Quarter 2025 Results

Key Financial Results: Net Income was $319 million, translating to diluted earnings per share ("EPS") of $4.24, up 11% from a year ago Adjusted EPS* increased 22% year-over-year to $5.15 Gross profit* increased 19% year-over-year to $1,273 million Core G…

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives …

EverCommerce Announces First Quarter 2025 Financial Results

EverCommerce Announces First Quarter 2025 Financial Results

DENVER, May 08, 2025 (GLOBE NEWSWIRE) -- EverCommerce Inc. ("EverCommerce" or the "Company") (NASDAQ: EVCM), a leading service commerce platform, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial …

Rumble Reports First Quarter 2025 Results

Rumble Reports First Quarter 2025 Results

~ Revenue up 34% Year-over-Year to $23.7 Million ~ ~ Rumble Cloud Secures Contract with Government of El Salvador ~ ~ Significantly Improved MAU Retention Compared to 2022 Mid-Term Elections ~ ~ Tether Investment Completed, Balance Sheet Solidified ~ …

AvePoint Announces First Quarter 2025 Financial Results

AvePoint Announces First Quarter 2025 Financial Results

First quarter SaaS revenue of $68.9 million, representing 34% year-over-year growth, 37% on a constant currency basis First quarter Total revenue of $93.1 million, representing 25% year-over-year growth, 27% on a constant currency basis Total ARR of $345.5 …

Fulcrum Therapeutics to Participate in Upcoming May Conferences

Fulcrum Therapeutics to Participate in Upcoming May Conferences

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …

Cytek Biosciences Reports First Quarter 2025 Financial Results

Cytek Biosciences Reports First Quarter 2025 Financial Results

FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First …

Cibus Reports First Quarter Financial Results and Provides Year-to-Date Business Update for 2025

Cibus Reports First Quarter Financial Results and Provides Year-to-Date Business Update for 2025

Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and HT3 traits with customer germplasm integration underway …

Fidus Investment Corporation Announces First Quarter 2025 Financial Results

Fidus Investment Corporation Announces First Quarter 2025 Financial Results

Board of Directors Declared Total Dividends of $0.54 per Share for Second Quarter 2025 Base Dividend of $0.43 and Supplemental Dividend of $0.11 Per Share EVANSTON, Ill., May 08, 2025 (GLOBE NEWSWIRE) -- Fidus Investment Corporation (NASDAQ:FDUS) (“Fidus” …

Treace Medical Concepts Reports First Quarter 2025 Financial Results

Treace Medical Concepts Reports First Quarter 2025 Financial Results

PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities …

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2027 -- BERKELEY, Calif., May …

Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates

Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates

Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with …

IBEX Reports Record Quarterly Revenue and EPS, Returns to Double-Digit Growth, Raises Fiscal Year Guidance

IBEX Reports Record Quarterly Revenue and EPS, Returns to Double-Digit Growth, Raises Fiscal Year Guidance

Quarterly revenue grew 11% versus prior year quarter - highest growth in ten quarters Adjusted EPS of $0.82 - an increase of 18% to prior year quarter Makes strategic entry into India - launching with leading healthcare client Board authorizes a new $15 …

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data …

Karat Packaging Reports 2025 First Quarter Financial Results

Karat Packaging Reports 2025 First Quarter Financial Results

— Strong revenue growth and well-positioned ahead of the global trade uncertainty — CHINO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Karat Packaging Inc. (Nasdaq: KRT) (“Karat” or the “Company”), a specialty distributor and manufacturer of environmentally …

Lantronix Reports Results for Third Quarter of Fiscal 2025

Lantronix Reports Results for Third Quarter of Fiscal 2025

Third Quarter Net Revenue of $28.5 Million Third Quarter GAAP EPS of ($0.10) Third Quarter Non-GAAP EPS of $0.03 IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for the Internet of …

TELA Bio Reports First Quarter 2025 Financial Results

TELA Bio Reports First Quarter 2025 Financial Results

MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended …

The Joint Corp. Reports First Quarter 2025 Financial Results

The Joint Corp. Reports First Quarter 2025 Financial Results

- Grew revenue from continuing operations 7% compared to Q1 2024 - - Increased system-wide sales 5% for Q1 2025, demonstrating economic resilience - SCOTTSDALE, Ariz., May 08, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, …

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service